DDInter298 DDInter1147
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Carboplatin (Compound) treats esophageal cancer (Disease)
Carboplatin (Compound) binds GSTM1 (Gene)
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Carboplatin (Compound) causes Venous thrombosis (Side Effect)